Edition:
United States

Profile: Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

4.80EUR
19 Oct 2018
Change (% chg)

€-0.00 (-0.04%)
Prev Close
€4.81
Open
€4.82
Day's High
€4.95
Day's Low
€4.78
Volume
98,854
Avg. Vol
106,135
52-wk High
€10.30
52-wk Low
€4.33

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. In February 2014, it acquired full development and commercialization rights to the anti-NKG2A antibody, a immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.

Company Address

Innate Pharma SA

117 avenue de Luminy, Bp 30191
MARSEILLE     13009
P: +334.30303030
F: +334.30303000

Company Web Links